India’s ambition to become a global leader in AI-driven diagnostics hinges on establishing a supportive policy framework, according to industry experts. The Indian medical technology sector is gaining recognition as a sunrise industry, fueled by an increasing demand for healthcare, technological advancements, and robust government support. Currently valued at approximately $14 billion, the market for medical devices in India is projected to double to $30 billion by 2030, with artificial intelligence (AI) expected to play a pivotal role.
Fujifilm, a major player in the medical technology landscape, is positioning itself to meet these burgeoning demands through a combination of advanced imaging technologies and AI solutions. In a recent interview, Koji Wada, Managing Director of Fujifilm India’s Healthcare Division, outlined the company’s growth trajectory and plans for the coming year. In 2025, Fujifilm India witnessed substantial double-digit growth across its healthcare segment, with CT and MRI systems becoming essential components in tertiary hospitals and advanced diagnostic centers. Endoscopy services surged, achieving a remarkable 30% year-on-year growth, marking India as one of Fujifilm’s fastest-growing markets globally.
With over 79,000 imaging systems installed across the country, a significant number of these are located in Tier 2 and Tier 3 cities. This expansion is supported by Fujifilm’s extensive service and training network, enhancing equipment uptime and clinician training. The year was also significant for infrastructure, with the inauguration of a new corporate headquarters in Gurugram, which serves as a medical contact center. Fujifilm’s commitment to public health was evident as the company screened more than 125,000 individuals for tuberculosis across 15 states and engaged over 100,000 women in breast cancer awareness initiatives.
Looking ahead to 2026, Fujifilm plans to sharpen its focus on innovation and partnerships. A new state-of-the-art endoscopy service facility will be established to strengthen its after-sales ecosystem. The company aims to anchor its operations in India through “Make in India,” actively exploring localized manufacturing. Fujifilm intends to expand its range of AI-powered diagnostic platforms and personalized screening solutions, particularly in underserved Tier 2 and Tier 3 markets. Collaborations with Indian technology firms and partnerships through NURA aim to enhance preventive healthcare efforts, aligning with the broader goal of making healthcare accessible to all Indians.
Fujifilm’s achievements in Tier 2 and Tier 3 cities underscore the democratization of advanced diagnostics beyond metropolitan areas. The company’s substantial installed base is bolstered by a robust service network that ensures equipment reliability and continuous professional development for healthcare providers. Strong partnerships with local governments, private diagnostic operators, and NGOs have been instrumental in building trust and expanding access to healthcare solutions.
Financially, Fujifilm India has consistently reported double-digit growth over the past three to five years, with specific segments like endoscopy and AI-driven solutions like CAD EYE achieving notable annual increases. In FY24, revenue growth reached 16%, and expectations for FY25-26 remain optimistic, driven by ongoing demand for AI diagnostics and expansion into unexplored markets.
AI’s role in healthcare diagnostics is evolving rapidly in India, facilitating earlier and more accurate disease detection. In radiology, AI enhances the identification of critical abnormalities, automating processes that improve diagnostic accuracy. In endoscopy, advancements have improved detection rates significantly, particularly for cancer diagnoses. This technological shift is vital for regions with limited access to specialists, as AI assists general practitioners in image interpretation and supports large-scale screening initiatives.
Despite the promising landscape, the AI healthcare market in India faces several challenges, including fragmented data systems and evolving regulatory frameworks. Fujifilm is addressing these challenges by localizing solutions to fit India’s unique landscape. The company emphasizes the importance of empowering clinicians through comprehensive training and support, enabling them to effectively utilize AI tools.
Fujifilm’s involvement in public-private partnerships for tele-radiology and advanced cancer screening further illustrates its commitment to impactful healthcare delivery in underserved regions. The company advocates for a conducive policy environment to accelerate the growth of AI-driven medical devices. Supportive measures from the government, including incentives for local manufacturing and streamlined regulatory processes, could bolster India’s position as a global hub for AI healthcare solutions.
Ultimately, as India aims to enhance its healthcare infrastructure, the integration of AI into diagnostics and medical devices will be crucial. Fujifilm India is poised to align its strategies with national priorities, ensuring that advanced healthcare solutions become accessible across the entire country.
MAGA Republicans Express Concerns Over AI’s Impact on Jobs Amid Trump’s Expansion Push
OpenAI’s Rogue AI Safeguards: Decoding the 2025 Safety Revolution
US AI Developments in 2025 Set Stage for 2026 Compliance Challenges and Strategies
Trump Drafts Executive Order to Block State AI Regulations, Centralizing Authority Under Federal Control
California Court Rules AI Misuse Heightens Lawyer’s Responsibilities in Noland Case
